Ferrer

  • Patients
  • Healthcare professionals
  • Ethical channel
  • Join us
  • News
  • Contact
EN

Navegación principal

  • We are Ferrer
    • Ferrer for good
    • Annual reports
    • Ethics and compliance
    • Transparency
    • Management team
    • Our history
  • Great People
  • Liveable Planet
  • Collective Action
  • Science
    • R&D Strategy
    • Pipeline
    • Our technologies
    • Clinical trials
    • Expanded Access Programs
  • Our Activities
    • A global presence
    • Pharmaceuticals
    • Active ingredients (APIs)
    • Business development
    • Manufacturing and distribution
EnglishEspañolCatalàNederlandsPortuguês, PortugalČeštinaFrançaisDeutschPolski

News

All of Ferrer’s information, just a click away

  1. Home
  2. News
normal

We allocate, on average, more than 40% of our profits to social and environmental projects for the third consecutive year

.
Wed, 07/26/2023 - 10:13

Ferrer4Future launches its open innovation challenge to drive digital solutions for ALS

.
Fri, 06/23/2023 - 07:24

We extend our clinical study in amyotrophic lateral sclerosis (ALS)

.
Thu, 06/22/2023 - 06:30

We’ve been awarded EcoVadis GOLD Rating!

.
Thu, 03/30/2023 - 09:29

Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP)

.
Wed, 02/22/2023 - 09:30

We achieve Great Place To Work certification in 5 countries

.
Tue, 11/29/2022 - 18:17

More than 500 people from Ferrer participate in positive impact activities in nine countries on the Days for Good

.
Fri, 10/07/2022 - 10:02

The polypill reduces cardiovascular mortality by 33% in patients treated after myocardial infarction

.
Thu, 08/25/2022 - 11:55

We invested more than 60% of our net profits in social and environmental causes

.
Thu, 07/28/2022 - 13:56

We bring ALSton the dragon to life to raise awareness of ALS

.
Tue, 06/21/2022 - 09:53
  • Cargar más
For requests for interviews or information, please contact the Communications Department

CONTACT US

alternatively, please dial +34 936 003 779

See more

R&D Strategy
Business Development

Connect

  • Contact
  • Join us
  • Press

B corp

Redes sociales footer

  • Facebook
  • linkedin
  • Youtube
  • Instagram
  • Twitter

European Union - European Regional Development Fund (ERDF)

Legal footer

  • Legal Notice
  • Privacy policy
  • Cookies policy

© 2025 Copyright Grupo Ferrer Internacional, S.A. All rights reserved.

Según la legislación vigente la información que precisa ver se considera información dirigida exclusivamente al profesional sanitario.

¿Es usted profesional sanitario?